US · Healthcare · Biotechnology
EPS came in at -0.11 against a street estimate of -0.11 — a beat of 0.0%.
Analysts rate Trevi Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $28.18.
CONFIDENT Trevi initiated two Phase III trials in IPF chronic cough (OCEAN-1, OCEAN-2) and Phase IIb in refractory chronic cough (LAKE) in Q2 2026. Cash runway extends to 2030. Competitor GSK exited RCC, leaving Trevi alone in three indications. Q2 2026 No geographic breakdown provided in earnings call. Analysts pressed on RCC market fragmentation post-GSK exit, SSRE impact, and non-IPF ILD trial design. Management emphasized specialty focus to protect IPF/ILD pricing, downplayed sample-size risk, and deferred detailed non-IPF protocol to pending FDA meeting. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| NEA Management Company, LLC | 9.28% |
| BlackRock Inc | 7.19% |
| Frazier Life Sciences Management, L.P. | 6.98% |
| FMR Inc | 5.64% |
| Wellington Management Company LLP | 3.99% |
| Vivo Capital, LLC | 3.58% |
| Vanguard Capital Management, LLC | 3.49% |
| Marshall Wace Asset Management Ltd | 2.78% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 TREVI THERAPEUTICS, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash position: $54.3 million in cash and cash equivalents as of June | 2026-08-06 |
| Results announced · Q3 2026 TREVI THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $318.9 million as of June 30, 2026 (comprised of $54.3 millio | 2026-08-06 |
| Charter / bylaws change · Q2 2026 TREVI THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 3, 2026 • Authorized common shares increased from 200,000,000 to | 2026-06-04 |
| Quarterly report · Q1 2026 TREVI THERAPEUTICS, INC. – FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash and Marketable Securities Combined: $171.8 mi | 2026-05-05 |
| Results announced · Q2 2026 TREVI THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position at end of Q1 2026: $171.8 million (cash, cash equivalents, and | 2026-05-05 |
| Proxy statement · Q2 2026 TREVI THERAPEUTICS, INC. - 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of one Class I director to serve until the 2029 | 2026-04-21 |
| Results announced · Q2 2026 TREVI THERAPEUTICS, INC. – UNDERWRITING AGREEMENT SUMMARY HEADLINE NUMBERS • Company issuing 11,600,000 shares of common stock (Initial Shares) via | 2026-04-17 |
| Annual report FY2025 TREVI THERAPEUTICS, INC. — 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Company: Trevi Therapeutics, Inc. (Nasdaq: TRVI) — clinical-sta | 2026-03-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Trevi Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.